table of contents table of contents

Home » Biology Articles » Cell biology » DNA and the chromosome – varied targets for chemotherapy » References

- DNA and the chromosome – varied targets for chemotherapy

1.   Hurley LH: DNA and its associated processes as targets for cancer therapy.Nat Rev Cancer 2002, 2:188-200.       2.   Gieseg MA, Matejovic J, Denny WA: Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA.Anticancer Drug Des 1999, 14:77-84.         3.   Herzig MC, Trevino AV, Arnett B, Woynarowski JM: Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific.Biochemistry 1999, 38:14045-14055.       4.   Woynarowski JM, Napier C, Trevino AV, Arnett B: Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity.Biochemistry 2000, 39:9917-9927.       5.   Herzig MC, Rodriguez KA, Trevino AV, Dziegielewski J, Arnett B, Hurley L, Woynarowski JM: The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level.Biochemistry 2002, 41:1545-1555.       6.   Woynarowski JM, Trevino AV, Rodriguez KA, Hardies SC, Benham CJ: AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs.J Biol Chem 2001, 276:40555-40566.       7.   Dudouet B, Burnett R, Dickinson LA, Wood MR, Melander C, Belitsky JM, Edelson B, Wurtz N, Briehn C, Dervan PB, Gottesfeld JM: Accessibility of nuclear chromatin by DNA binding polyamides.Chem Biol 2003, 10:859-867.       8.   Abu-Daya A, Brown PM, Fox KR: DNA sequence preferences of several AT-selective minor groove binding ligands.Nucleic Acids Res 1995, 23:3385-3392.       9.   Abu-Daya A, Fox KR: Interaction of minor groove binding ligands with long AT tracts.Nucleic Acids Res 1997, 25:4962-4969.       10.   Bremer RE, Szewczyk JW, Baird EE, Dervan PB: Recognition of the DNA minor groove by pyrrole-imidazole polyamides: comparison of desmethyl- and N-methylpyrrole.Bioorg Med Chem 2000, 8:1947-1955.       11.   Harshman KD, Dervan PB: Molecular recognition of B-DNA by Hoechst 33258.Nucleic Acids Res 1985, 13:4825-4835.       12.   Schultz PG, Dervan PB: Distamycin and penta-N-methylpyrrolecarboxamide binding sites on native DNA. A comparison of methidiumpropyl-EDTA-Fe(II) footprinting and DNA affinity cleaving.J Biomol Struct Dyn 1984, 1:1133-1147.       13.   Hurley LH: Secondary DNA structures as molecular targets for cancer therapeutics.Biochem Soc Trans 2001, 29:692-696.       14.   Gniazdowski M, Denny WA, Nelson SM, Czyz M: Transcription factors as targets for DNA-interacting drugs.Curr Med Chem 2003, 10:909-924.       15.   Woynarowski JM: Targeting critical regions in genomic DNA with AT-specific anticancer drugs.Biochim Biophys Acta 2002, 1587:300-308.       16.   Reeves R, Beckerbauer L: HMGI/Y proteins: flexible regulators of transcription and chromatin structure.Biochim Biophys Acta 2001, 1519:13-29.       17.   Reeves R, Beckerbauer LM: HMGA proteins as therapeutic drug targets.Prog Cell Cycle Res 2003, 5:279-286.       18.   Agresti A, Bianchi ME: HMGB proteins and gene expression.Curr Opin Genet Dev 2003, 13:170-178.       19.   Catez F, Lim JH, Hock R, Postnikov YV, Bustin M: HMGN dynamics and chromatin function.Biochem Cell Biol 2003, 81:113-122.       20.   Thomas JO: HMG1 and 2: architectural DNA-binding proteins.Biochem Soc Trans 2001, 29:395-401.       21.   Chiang SY, Welch J, Rauscher F. J., 3rd, Beerman TA: Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA.Biochemistry 1994, 33:7033-7040.       22.   Chow CS, Whitehead JP, Lippard SJ: HMG domain proteins induce sharp bends in cisplatin-modified DNA.Biochemistry 1994, 33:15124-15130.       23.   Jung Y, Mikata Y, Lippard SJ: Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA.J Biol Chem 2001, 276:43589-43596.       24.   Jung Y, Lippard SJ: Nature of full-length HMGB1 binding to cisplatin-modified DNA.Biochemistry 2003, 42:2664-2671.         25.   Welch JJ, Rauscher F. J., 3rd, Beerman TA: Targeting DNA-binding drugs to sequence-specific transcription factor.DNA complexes. Differential effects of intercalating and minor groove binding drugs.J Biol Chem 1994, 269:31051-31058.       26.   Beckerbauer L, Tepe JJ, Cullison J, Reeves R, Williams RM: FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo.Chem Biol 2000, 7:805-812.       27.   Beckerbauer L, Tepe JJ, Eastman RA, Mixter PF, Williams RM, Reeves R: Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome.Chem Biol 2002, 9:427-441.       28.   d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP: A DNA damage checkpoint response in telomere-initiated senescence.Nature 2003, 426:194-198.       29.   Weinmann AS, Farnham PJ: Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation.Methods 2002, 26:37-47.       30.   Wells J, Farnham PJ: Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation.Methods 2002, 26:48-56.       31.   Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD: G-quadruplexes as targets for drug design.Pharmacol Ther 2000, 85:141-158.       32.   Han H, Hurley LH: G-quadruplex DNA: a potential target for anti-cancer drug design.Trends Pharmacol Sci 2000, 21:136-142.       33.   Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.Proc Natl Acad Sci U S A 2002, 99:11593-11598.       34.   Simonsson T, Pecinka P, Kubista M: DNA tetraplex formation in the control region of c-myc.Nucleic Acids Res 1998, 26:1167-1172.       35.   Simonsson T, Pribylova M, Vorlickova M: A nuclease hypersensitive element in the human c-myc promoter adopts several distinct i-tetraplex structures.Biochem Biophys Res Commun 2000, 278:158-166.       36.   Simonsson T, Sjoback R: DNA tetraplex formation studied with fluorescence resonance energy transfer.J Biol Chem 1999, 274:17379-17383.       37.   Phillips K, Dauter Z, Murchie AI, Lilley DM, Luisi B: The crystal structure of a parallel-stranded guanine tetraplex at 0.95 A resolution.J Mol Biol 1997, 273:171-182.       38.   Brown K: Visualizing nuclear proteins together with transcribed and inactive genes in structurally preserved cells.Methods 2002, 26:10-18.       39.   Brown KE: Chromatin folding and gene expression: new tools to reveal the spatial organization of genes.Chromosome Res 2003, 11:423-433.       40.   Brown K: Nuclear structure, gene expression and development.Crit Rev Eukaryot Gene Expr 1999, 9:203-212       41.   Dolnik AV, Kuznetsova IS, Voronin AP, Podgornaya OI: Telomere-binding TRF2/MTBP localization during mouse spermatogenesis and cell cycle of the mouse cells L929.J Anti Aging Med 2003, 6:107-121.       42.   Sidorova JM, Breeden LL: Precocious G1/S transitions and genomic instability: the origin connection.Mutat Res 2003, 532:5-19.         43.   Barbour L, Xiao W: Regulation of alternative replication bypass pathways at stalled replication forks and its effects on genome stability: a yeast model.Mutat Res 2003, 532:137-155.       44.   Holmquist GP, Maher VM: The bypass of DNA lesions by DNA and RNA polymerases.Mutat Res 2002, 510:1-7.       45.   Hu W, Kavanagh JJ: Anticancer therapy targeting the apoptotic pathway.Lancet Oncol 2003, 4:721-729.       46.   Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective.Nature 2000, 408:433-439.       47.   Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.Genes Dev 2000, 14:927-939.       48.   Fei P, El-Deiry WS: P53 and radiation responses.Oncogene 2003, 22:5774-5783.       49.   Iliakis G, Wang Y, Guan J, Wang H: DNA damage checkpoint control in cells exposed to ionizing radiation.Oncogene 2003, 22:5834-5847.       50.   Goodarzi AA, Block WD, Lees-Miller SP: The role of ATM and ATR in DNA damage-induced cell cycle control.Prog Cell Cycle Res 2003, 5:393-411.       51.   Kastan MB, Lim DS: The many substrates and functions of ATM.Nat Rev Mol Cell Biol 2000, 1:179-186.       52.   McGowan CH: Checking in on Cds1 (Chk2): A checkpoint kinase and tumor suppressor.Bioessays 2002, 24:502-511.       53.   Bartek J, Falck J, Lukas J: CHK2 kinase--a busy messenger.Nat Rev Mol Cell Biol 2001, 2:877-886.       54.   Bartek J, Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer.Cancer Cell 2003, 3:421-429.       55.   Rhind N, Russell P: Mitotic DNA damage and replication checkpoints in yeast.Curr Opin Cell Biol 1998, 10:749-758.       56.   Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, Kastan MB: ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.Nature 2000, 404:613-617.       57.   Kim ST, Lim DS, Canman CE, Kastan MB: Substrate specificities and identification of putative substrates of ATM kinase family members.J Biol Chem 1999, 274:37538-37543.       58.   Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.Science 1999, 286:1162-1166.         59.   Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.Science 1999, 285:747-750.       60.   Hansson J, Lewensohn R, Ringborg U, Nilsson B: Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells.Cancer Res 1987, 47:2631-2637.       61.   Pieper RO, Futscher BW, Erickson LC: Transcription-terminating lesions induced by bifunctional alkylating agents in vitro.Carcinogenesis 1989, 10:1307-1314.       62.   Wang AL, Tew KD: Increased glutathione-S-transferase activity in a cell line with acquired resistance to nitrogen mustards.Cancer Treat Rep 1985, 69:677-682.       63.   Suzukake K, Vistica BP, Vistica DT: Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.Biochem Pharmacol 1983, 32:165-167.       64.   Brendel M, Ruhland A: Relationships between functionality and genetic toxicology of selected DNA-damaging agents.Mutat Res 1984, 133:51-85.       65.   Palmer RG, Denman AM: Malignancies induced by chlorambucil.Cancer Treat Rev 1984, 11:121-129.       66.   Schein PS, O'Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, Wiernik PH, Ziegler JL, DeVita VT: Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).Cancer 1974, 34:993-1000.       67.   Cohen GL, Falkson CI: Current treatment options for malignant melanoma.Drugs 1998, 55:791-799.       68.   Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma.Clin Cancer Res 2000, 6:2585-2597.       69.   Bradner WT: Mitomycin C: a clinical update.Cancer Treat Rev 2001, 27:35-50.       70.   Ramel C: Mini- and microsatellites.Environ Health Perspect 1997, 105 Suppl 4:781-789.       71.   Debrauwere H, Gendrel CG, Lechat S, Dutreix M: Differences and similarities between various tandem repeat sequences: minisatellites and microsatellites.Biochimie 1997, 79:577-586.       72.   Jackson JA, Trevino AV, Herzig MC, Herman TS, Woynarowski JM: Matrix attachment region (MAR) properties and abnormal expansion of AT island minisatellites in FRA16B fragile sites in leukemic CEM cells.Nucleic Acids Res 2003, 31:6354-6364.       73.   Hanka LJ, Dietz A, Gerpheide SA, Kuentzel SL, Martin DG: CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism.J Antibiot (Tokyo) 1978, 31:1211-1217.       74.   Atwell GJ, Tercel M, Boyd M, Wilson WR, Denny WA: Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbomyl]-1,2-dihydre-3H-bene[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: new DNA minor groove alkylating agents.J.Org. Chem. 1998, 63:9414-9420.       75.   Reddy BS, Sharma SK, Lown JW: Recent developments in sequence selective minor groove DNA effectors.Curr Med Chem 2001, 8:475-508.       76.   Woynarowski JM, McHugh MM, Gawron LS, Beerman TA: Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA.Biochemistry 1995, 34:13042-13050.       77.   McHugh MM, Woynarowski JM, Mitchell MA, Gawron LS, Weiland KL, Beerman TA: CC-1065 bonding to intracellular and purified SV40 DNA: site specificity and functional effects.Biochemistry 1994, 33:9158-9168.       78.   Cobuzzi R. J., Jr., Burhans WC, Beerman TA: Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin.J Biol Chem 1996, 271:19852-19859.       79.   Woynarowski JM, Beerman TA: Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells.Biochim Biophys Acta 1997, 1353:50-60.       80.   Weinberger M, Trabold PA, Lu M, Sharma K, Huberman JA, Burhans WC: Induction by adozelesin and hydroxyurea of origin recognition complex-dependent DNA damage and DNA replication checkpoints in Saccharomyces cerevisiae.J Biol Chem 1999, 274:35975-35984.       81.   McHugh MM, Kuo SR, Walsh-O'Beirne MH, Liu JS, Melendy T, Beerman TA: Bizelesin, a bifunctional cyclopropylpyrroloindole alkylating agent, inhibits simian virus 40 replication in trans by induction of an inhibitor.Biochemistry 1999, 38:11508-11515.       82.   Wang Y, Beerman TA, Kowalski D: Antitumor drug adozelesin differentially affects active and silent origins of DNA replication in yeast checkpoint kinase mutants.Cancer Res 2001, 61:3787-3794.       83.   Sun D, Hurley LH: Binding of Sp1 to the 21-bp repeat region of SV40 DNA: effect of intrinsic and drug-induced DNA bending between GC boxes.Gene 1994, 149:165-172.       84.   Cameron L, Thompson AS: Determination of the structural role of the linking moieties in the DNA binding of adozelesin.Biochemistry 2000, 39:5004-5012.       85.   Black AR, Black JD, Azizkhan-Clifford J: Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer.J Cell Physiol 2001, 188:143-160.       86.   Dervan PB, Edelson BS: Recognition of the DNA minor groove by pyrrole-imidazole polyamides.Curr Opin Struct Biol 2003, 13:284-299.       87.   Gottesfeld JM, Melander C, Suto RK, Raviol H, Luger K, Dervan PB: Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides.J Mol Biol 2001, 309:615-629.       88.   Zimmer C, Wahnert U: Nonintercalating DNA-binding ligands: specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material.Prog Biophys Mol Biol 1986, 47:31-112.       89.   Ehley JA, Melander C, Herman D, Baird EE, Ferguson HA, Goodrich JA, Dervan PB, Gottesfeld JM: Promoter scanning for transcription inhibition with DNA-binding polyamides.Mol Cell Biol 2002, 22:1723-1733.       90.   Dickinson LA, Trauger JW, Baird EE, Dervan PB, Graves BJ, Gottesfeld JM: Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappaB, and DNA by a designed DNA-binding ligand.J Biol Chem 1999, 274:12765-12773.       91.   Wurtz NR, Dervan PB: Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates.Chem Biol 2000, 7:153-161.       92.   Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM: Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.J Virol 2002, 76:12349-12354       93.   Wang YD, Dziegielewski J, Wurtz NR, Dziegielewska B, Dervan PB, Beerman TA: DNA crosslinking and biological activity of a hairpin polyamide-chlorambucil conjugate.Nucleic Acids Res 2003, 31:1208-1215.       94.   Wang YD, Dziegielewski J, Chang AY, Dervan PB, Beerman TA: Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate.J Biol Chem 2002, 277:42431-42437.       95.   D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT: Unique features of the mode of action of ET-743.Oncologist 2002, 7:210-216.       96.   Schwartsmann G, Da Rocha AB, Mattei J, Lopes R: Marine-derived anticancer agents in clinical trials.Expert Opin Investig Drugs 2003, 12:1367-1383.       97.   Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.Biochemistry 1996, 35:13303-13309.       98.   Garcia-Nieto R, Manzanares I, Cuevas C, Gago F: Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?J Med Chem 2000, 43:4367-4369.       99.   Hurley LH, Zewail-Foote M: The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.Adv Exp Med Biol 2001, 500:289-299.       100.   Zewail-Foote M, Hurley LH: Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.J Am Chem Soc 2001, 123:6485-6495.       101.   Zewail-Foote M, Hurley LH: Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.J Med Chem 1999, 42:2493-2497.       102.   Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, Mantovani R, D'Incalci M: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA.Anticancer Drug Des 1999, 14:179-186.       103.   Jin S, Gorfajn B, Faircloth G, Scotto KW: Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.Proc Natl Acad Sci U S A 2000, 97:6775-6779.       104.   Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.Proc Natl Acad Sci U S A 2000, 97:6780-6784.       105.   Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW: Ecteinascidin-743 inhibits activated but not constitutive transcription.Cancer Res 2002, 62:3377-3381.       106.   Martinez EJ, Owa T, Schreiber SL, Corey EJ: Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.Proc Natl Acad Sci U S A 1999, 96:3496-3501.       107.   Martinez EJ, Corey EJ, Owa T: Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.Chem Biol 2001, 8:1151-1160.       108.   Adams J, Elliott PJ: New agents in cancer clinical trials.Oncogene 2000, 19:6687-6692.       109.   Marco E, Garcia-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F: A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.J Med Chem 2002, 45:871-880.       110.   Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M: Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.Int J Cancer 2001, 92:583-588.       111.   Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.Nat Med 2001, 7:961-966.       112.   Usdin K, Grabczyk E: DNA repeat expansions and human disease.Cell Mol Life Sci 2000, 57:914-931.       113.   Rhodes D, Fairall L, Simonsson T, Court R, Chapman L: Telomere architecture.EMBO Rep 2002, 3:1139-1145       114.   Rezler EM, Bearss DJ, Hurley LH: Telomere inhibition and telomere disruption as processes for drug targeting.Annu Rev Pharmacol Toxicol 2003, 43:359-379.       115.   Kanoh J, Ishikawa F: Composition and conservation of the telomeric complex.Cell Mol Life Sci 2003, 60:2295-2302.       116.   Meeker AK, De Marzo AM: Recent advances in telomere biology: implications for human cancer.Curr Opin Oncol 2004, 16:32-38.       117.   Saretzki G: Telomerase inhibition as cancer therapy.Cancer Lett 2003, 194:209-219.       118.   Saretzki G, von Zglinicki T: Telomerase as a promising target for human cancer gene therapy.Drugs Today (Barc) 2003, 39:265-276.         119.   Blasco MA: Telomeres and cancer: a tale with many endings.Curr Opin Genet Dev 2003, 13:70-76.       120.   Rezler EM, Bearss DJ, Hurley LH: Telomeres and telomerases as drug targets.Curr Opin Pharmacol 2002, 2:415-423.       121.   Sun D, Hurley LH: Targeting telomeres and telomerase.Methods Enzymol 2001, 340:573-592.       122.   Saretzki G, Ludwig A, von Zglinicki T, Runnebaum IB: Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells.Cancer Gene Ther 2001, 8:827-834.       123.   Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC: Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.Mol Cancer Ther 2003, 2:825-833.       124.   Tanious FA, Jenkins TC, Neidle S, Wilson WD: Substituent position dictates the intercalative DNA-binding mode for anthracene-9,10-dione antitumor drugs.Biochemistry 1992, 31:11632-11640.       125.   Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, Jenkins TC, Neidle S, Hurley LH: Inhibition of human telomerase by a G-quadruplex-interactive compound.J Med Chem 1997, 40:2113-2116.       126.   Harrison RJ, Cuesta J, Chessari G, Read MA, Basra SK, Reszka AP, Morrell J, Gowan SM, Incles CM, Tanious FA, Wilson WD, Kelland LR, Neidle S: Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.J Med Chem 2003, 46:4463-4476.       127.   Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR: A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.Mol Pharmacol 2002, 61:1154-1162.       128.   Anantha NV, Azam M, Sheardy RD: Porphyrin binding to quadrupled T4G4.Biochemistry 1998, 37:2709-2714.       129.   Han H, Langley DR, Rangan A, Hurley LH: Selective interactions of cationic porphyrins with G-quadruplex structures.J Am Chem Soc 2001, 123:8902-8913.       130.   Han H, Cliff CL, Hurley LH: Accelerated assembly of G-quadruplex structures by a small molecule.Biochemistry 1999, 38:6981-6986.       131.   Gazin C, Dupont de Dinechin S, Hampe A, Masson JM, Martin P, Stehelin D, Galibert F: Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon.Embo J 1984, 3:383-387.       132.   Cooney M, Czernuszewicz G, Postel EH, Flint SJ, Hogan ME: Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro.Science 1988, 241:456-459.       133.   Postel EH, Flint SJ, Kessler DJ, Hogan ME: Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels.Proc Natl Acad Sci U S A 1991, 88:8227-8231.       134.   Kang CH, Berger I, Lockshin C, Ratliff R, Moyzis R, Rich A: Crystal structure of intercalated four-stranded d(C3T) at 1.4 A resolution.Proc Natl Acad Sci U S A 1994, 91:11636-11640.       135.   Gehring K, Leroy JL, Gueron M: A tetrameric DNA structure with protonated cytosine.cytosine base pairs.Nature 1993, 363:561-565.       136.   Chen L, Cai L, Zhang X, Rich A: Crystal structure of a four-stranded intercalated DNA: d(C4).Biochemistry 1994, 33:13540-13546.       137.   Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ: The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.Mol Cancer Ther 2002, 1:565-573.       138.   Wadkins RM: Targeting DNA secondary structures.Curr Med Chem 2000, 7:1-15       139.   Wadkins RM, Tung CS, Vallone PM, Benight AS: The role of the loop in binding of an actinomycin D analog to hairpins formed by single-stranded DNA.Arch Biochem Biophys 2000, 384:199-203.       140.   Chen FM, Sha F, Chin KH, Chou SH: Unique actinomycin D binding to self-complementary d(CXYGGCCY'X'G) sequences: duplex disruption and binding to a nominally base-paired hairpin.Nucleic Acids Res 2003, 31:4238-4246.         141.   Eichman BF, Vargason JM, Mooers BH, Ho PS: The Holliday junction in an inverted repeat DNA sequence: sequence effects on the structure of four-way junctions.Proc Natl Acad Sci U S A 2000, 97:3971-3976.       142.   West KL, Austin CA: Human DNA topoisomerase IIbeta binds and cleaves four-way junction DNA in vitro.Nucleic Acids Res 1999, 27:984-992.       143.   Zhong M, Rashes MS, Marky LA, Kallenbach NR: T-T base mismatches enhance drug binding at the branch site in a four-arm DNA junction.Biochemistry 1992, 31:8064-8071.       144.   Yang XL, Robinson H, Gao YG, Wang AH: Binding of a macrocyclic bisacridine and ametantrone to CGTACG involves similar unusual intercalation platforms.Biochemistry 2000, 39:10950-10957.       145.   Thorpe JH, Hobbs JR, Todd AK, Denny WA, Charlton P, Cardin CJ: Guanine specific binding at a DNA junction formed by d[CG(5-BrU)ACG](2) with a topoisomerase poison in the presence of Co(2+) ions.Biochemistry 2000, 39:15055-15061.       146.   Adams A, Guss JM, Collyer CA, Denny WA, Wakelin LP: A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)(2).Nucleic Acids Res 2000, 28:4244-4253.       147.   Teixeira SC, Thorpe JH, Todd AK, Powell HR, Adams A, Wakelin LP, Denny WA, Cardin CJ: Structural characterisation of bisintercalation in higher-order DNA at a junction-like quadruplex.J Mol Biol 2002, 323:167-171.       148.   Fox KR: Targeting DNA with triplexes.Curr Med Chem 2000, 7:17-37.       149.   Sarkar PS, Brahmachari SK: Intramolecular triplex potential sequence within a gene down regulates its expression in vivo.Nucleic Acids Res 1992, 20:5713-5718.       150.   Duval-Valentin G, de Bizemont T, Takasugi M, Mergny JL, Bisagni E, Helene C: Triple-helix specific ligands stabilize H-DNA conformation.J Mol Biol 1995, 247:847-858.       151.   Sehlstedt U, Aich P, Bergman J, Vallberg H, Norden B, Graslund A: Interactions of the antiviral quinoxaline derivative 9-OH-B220 [2, 3-dimethyl-6-(dimethylaminoethyl)- 9-hydroxy-6H-indolo-[2, 3-b]quinoxaline] with duplex and triplex forms of synthetic DNA and RNA.J Mol Biol 1998, 278:31-56.       152.   Arya DP, Micovic L, Charles I, Coffee R. L., Jr., Willis B, Xue L: Neomycin binding to Watson-Hoogsteen (W-H) DNA triplex groove: a model.J Am Chem Soc 2003, 125:3733-3744.       153.   Topcu Z: DNA topoisomerases as targets for anticancer drugs.J Clin Pharm Ther 2001, 26:405-416.       154.   Wall ME, Wani MC: Camptothecin. Discovery to clinic.Ann N Y Acad Sci 1996, 803:1-12.       155.   Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.Cancer Res 1988, 48:1722-1726.       156.   Berger JM, Gamblin SJ, Harrison SC, Wang JC: Structure and mechanism of DNA topoisomerase II.Nature 1996, 379:225-232.       157.   Larsen AK, Escargueil AE, Skladanowski A: Catalytic topoisomerase II inhibitors in cancer therapy.Pharmacol Ther 2003, 99:167-181.       158.   Hsiang YH, Wu HY, Liu LF: Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.Cancer Res 1988, 48:3230-3235.       159.   Prosperi E, Negri C, Marchese G, Ricotti GC: Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes.Cell Prolif 1994, 27:257-267.       160.   Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of camptothecin.Exp Cell Res 1991, 193:27-35.       161.   Goossens JF, Henichart JP, Dassonneville L, Facompre M, Bailly C: Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells.Eur J Pharm Sci 2000, 10:125-131.       162.   Kaufmann WK, Boyer JC, Estabrooks LL, Wilson SJ: Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.Mol Cell Biol 1991, 11:3711-3718.       163.   Zhang H, Wang JC, Liu LF: Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.Proc Natl Acad Sci U S A 1988, 85:1060-1064.       164.   Karpf AR, Jones DA: Reactivating the expression of methylation silenced genes in human cancer.Oncogene 2002, 21:5496-5503.       165.   Claus R, Lubbert M: Epigenetic targets in hematopoietic malignancies.Oncogene 2003, 22:6489-6496.       166.   Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes.J Mol Biol 1987, 196:261-282.       167.   Cross SH, Bird AP: CpG islands and genes.Curr Opin Genet Dev 1995, 5:309-314.       168.   Barlow DP: Gametic imprinting in mammals.Science 1995, 270:1610-1613.       169.   Goto T, Monk M: Regulation of X-chromosome inactivation in development in mice and humans.Microbiol Mol Biol Rev 1998, 62:362-378.       170.   Jones PA, Laird PW: Cancer epigenetics comes of age.Nat Genet 1999, 21:163-167.       171.   Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation.Cell 1980, 20:85-93.       172.   Bender CM, Zingg JM, Jones PA: DNA methylation as a target for drug design.Pharm Res 1998, 15:175-187.       173.   Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE: Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells.J Biol Chem 1997, 272:32260-32266.       174.   Leone G, Voso MT, Teofili L, Lubbert M: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.Clin Immunol 2003, 109:89-102.       175.   Leone G, Teofili L, Voso MT, Lubbert M: DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.Haematologica 2002, 87:1324-1341.       176.   Lubbert M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.Curr Top Microbiol Immunol 2000, 249:135-164.       177.   Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.Ann Intern Med 2001, 134:573-586.       178.   Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR: Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms.J Biol Chem 1999, 274:24250-24256.       179.   Bigey P, Knox JD, Croteau S, Bhattacharya SK, Theberge J, Szyf M: Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA. Hairpin antagonists of the human DNA methyltransferase.J Biol Chem 1999, 274:4594-4606.       180.   Yang XJ, Seto E: Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression.Curr Opin Genet Dev 2003, 13:143-153.       181.   Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF: Histone deacetylases: unique players in shaping the epigenetic histone code.Ann N Y Acad Sci 2003, 983:84-100.       182.   Fischle W, Wang Y, Allis CD: Histone and chromatin cross-talk.Curr Opin Cell Biol 2003, 15:172-183.       183.   Grewal SI, Moazed D: Heterochromatin and epigenetic control of gene expression.Science 2003, 301:798-802.       184.   Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals.Nat Genet 2003, 33 Suppl:245-254.       185.   Deckert J, Struhl K: Targeted recruitment of Rpd3 histone deacetylase represses transcription by inhibiting recruitment of Swi/Snf, SAGA, and TATA binding protein.Mol Cell Biol 2002, 22:6458-6470.       186.   Moazed D: Common themes in mechanisms of gene silencing.Mol Cell 2001, 8:489-498.       187.   Henderson C, Brancolini C: Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.Drug Resist Updat 2003, 6:247-256.       188.   Arts J, de Schepper S, Van Emelen K: Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.Curr Med Chem 2003, 10:2343-2350.       189.   De Schepper S, Bruwiere H, Verhulst T, Steller U, Andries L, Wouters W, Janicot M, Arts J, Van Heusden J: Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin.J Pharmacol Exp Ther 2003, 304:881-888.       190.   Vigushin DM, Coombes RC: Histone deacetylase inhibitors in cancer treatment.Anticancer Drugs 2002, 13:1-13.       191.   Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.Clin Cancer Res 2003, 9:3578-3588.       192.   Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.J Exp Ther Oncol 2002, 2:325-332.       193.   Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.Nature 1999, 401:188-193.       194.   Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies.Nat Rev Cancer 2001, 1:194-202.       195.   Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC: Molecular sequelae of histone deacetylase inhibition in human malignant B cells.Blood 2003, 101:4055-4062.       196.   Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications.Proc Natl Acad Sci U S A 2004, 101:540-545.       197.   Primeau M, Gagnon J, Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.Int J Cancer 2003, 103:177-184.       198.   Zhu WG, Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.Curr Med Chem Anti-Canc Agents 2003, 3:187-199.       199.   Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL: Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.Anticancer Drugs 2003, 14:193-202.       200.   Yang L, Mei Q, Zielinska-Kwiatkowska A, Matsui Y, Blackburn ML, Benedetti D, Krumm AA, Taborsky G. J., Jr., Chansky HA: An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B.Biochem J 2003, 369:651-657.       201.   Zhu WG, Lakshmanan RR, Beal MD, Otterson GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.Cancer Res 2001, 61:1327-1333.       202.   Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S: Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.Cancer Res 2003, 63:8420-8427.       203.   Ming LJ: Structure and function of "metalloantibiotics".Med Res Rev 2003, 23:697-762.       204.   Malina J, Kasparkova J, Natile G, Brabec V: Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts.Chem Biol 2002, 9:629-638.       205.   Cohen SM, Mikata Y, He Q, Lippard SJ: HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.Biochemistry 2000, 39:11771-11776.       206.   Pil PM, Lippard SJ: Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.Science 1992, 256:234-237.       207.   Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance.Oncogene 2003, 22:7265-7279.       208.   Wei M, Cohen SM, Silverman AP, Lippard SJ: Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins.J Biol Chem 2001, 276:38774-38780.       209.   Vichi P, Coin F, Renaud JP, Vermeulen W, Hoeijmakers JH, Moras D, Egly JM: Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP.Embo J 1997, 16:7444-7456.       210.   Hoffmann JS, Locker D, Villani G, Leng M: HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.J Mol Biol 1997, 270:539-543.       211.   He Q, Liang CH, Lippard SJ: Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.Proc Natl Acad Sci U S A 2000, 97:5768-5772.       212.   Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A: HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.Proc Natl Acad Sci U S A 1994, 91:10394-10398.       213.   Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ: Repair of cisplatin--DNA adducts by the mammalian excision nuclease.Biochemistry 1996, 35:10004-10013.       214.   Siddik ZH: Biochemical and molecular mechanisms of cisplatin resistance.Cancer Treat Res 2002, 112:263-284.       215.   Boulikas T, Vougiouka M: Cisplatin and platinum drugs at the molecular level. (Review).Oncol Rep 2003, 10:1663-1682.       216.   Roskoski R., Jr.: STI-571: an anticancer protein-tyrosine kinase inhibitor.Biochem Biophys Res Commun 2003, 309:709-717.       217.   Denny WA: Prodrug strategies in cancer therapy.Eur J Med Chem 2001, 36:577-595.    

rating: 3.21 from 38 votes | updated on: 18 Jun 2007 | views: 24220 |

Rate article: